GSK Advances Respiratory And Vaccine Growth With Key RSV And Asthma Moves [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
GSK (LSE:GSK) received European approval to broaden the age indication for its RSV vaccine Arexvy, expanding eligible adults beyond the original target group. The company launched Exdensur in the U.S., an ultra long acting biologic for severe asthma designed for a less frequent dosing schedule. GSK also completed key studies for vaccines and specialty drugs, marking progress in its respiratory and vaccine pipelines. For you as an investor, these updates sit squarely in the core of GSK's business, which is heavily focused on vaccines and respiratory medicines. The broader age label for Arexvy in Europe ties directly to long running efforts to address RSV in adults, while Exdensur adds another branded option in severe asthma, a segment where long term treatment is common. The recent study completions give GSK more clarity on how its pipeline may translate into future product launches and label expansions over time. Together, these developments show how management is leaning int
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Why OpenAI's drug royalties deal won't work [Yahoo! Finance]Yahoo! Finance
- Pfizer sets sights on R&D strategy amid modest FY25 results [Yahoo! Finance]Yahoo! Finance
- Latent TB Diagnostics Research Report 2026: Global Market Analysis and Forecasts 2025-2029 by Assay, Risk Factor, and Lab/Place with Executive and Consultant Guides [Yahoo! Finance]Yahoo! Finance
- Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 2/6/26 - Form 6-K
- 2/5/26 - Form S-8
- 1/29/26 - Form 6-K
- SNY's page on the SEC website